文献速递免疫规划卫生政策与健康促进

老年人使用标准剂量佐剂三价流感疫苗的成本效果评估

Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly.
PubMed 文献 · Vaccine · 2019-03-11

研究采用动态SEIR传播模型结合经济评估框架,分析佐剂三价流感疫苗(TIV-ADJ)在65岁及以上和75岁及以上人群中替代标准非佐剂三价疫苗(TIV)的成本效果。结果显示TIV-ADJ在两组目标年龄队列中均具有高度成本效果,增量成本效果比远低于每质量调整生命年(QALY)20000英镑,在30000英镑/QALY阈值下具有成本效果的概率超过90%。

要点

  • TIV-ADJ在65+和75+人群中增量成本效果比均远低于20000英镑/QALY。
  • 在30000英镑/QALY阈值下,TIV-ADJ具有成本效果的概率超过90%。
  • TIV对75+人群效果有限,该人群从更有效疫苗中获益最大。

核心结论

  • TIV-ADJ在65岁及以上和75岁及以上人群中均具有高度成本效果,从医疗提供者角度比TIV更具吸引力。

研究设计与样本

  • 采用动态SEIR型传播模型结合经济评估框架,评估TIV-ADJ在65+和75+年龄组中替代TIV的成本效果。

主要发现

  • 使用TIV-ADJ可减少全科医生咨询、住院和流感归因死亡。
  • TIV-ADJ在65+和75+队列中的增量成本效果比均远低于每QALY 20000英镑。
  • 在每QALY 30000英镑阈值下,TIV-ADJ具有成本效果的概率超过90%。

关键数值与推荐

  • 成本效果阈值:每QALY 20000英镑和30000英镑。
  • TIV-ADJ在30000英镑/QALY阈值下具有成本效果的概率超过90%。

临床怎么用

  • 在65+和75+老年人中可优先考虑使用TIV-ADJ替代TIV以提升保护效果。
  • 决策时应考虑TIV对75+人群效果有限,该人群从更有效疫苗中获益最大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite a long-standing vaccination programme, seasonal influenza remains a major public health problem in England, in particular for the elderly where a significant disease burden remains despite vaccine coverage approaching the WHO target of 75%. The recently licensed adjuvanted trivalent vaccines (TIV-ADJ) have been shown to offer greater protection for the elderly compared to the standard-dose non-adjuvanted trivalent vaccines (TIV), particularly for those individuals 75 years old and above for whom the TIV has limited effectiveness. We assessed the cost-effectiveness of the TIV-ADJ for use in the elderly. METHODS: We used a dynamic SEIR-type transmission model coupled with an economic evaluation framework, estimating the reduction in GP consultations, hospitalisations and influenza-attributable mortality. We assessed the optimal use of the TIV-ADJ by estimating the cost-effectiveness of programmes that used this vaccine in the 65+ and 75+ age groups. FINDINGS: The use of TIV-ADJ is highly cost-effective for both target age cohorts with incremental cost-effectiveness ratios well below the £20,000 per quality-adjusted life year (QALY) with over 90% probability that the vaccine is cost-effective at a cost-effectiveness threshold of £30,000 per QALY. INTERPRETATION: The increased protection provided across all three influenza vaccine sub-types makes TIV-ADJ a more attractive option than TIV from the perspective of the healthcare provider, driven by the increased efficacy against A(H3N2). When deciding on the optimal use of the newly available vaccine it is important to consider the fact that TIV has very limited effectiveness for the 75+ age group, who would therefore get the greatest benefit from a more effective vaccine. FUNDING: I-MOVE+ project (Integrated Monitoring of Vaccines in Europe) through the European Union's Horizon 2020 research and innovation programme under grant agreement #634446 and the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Respiratory Infections at Imperial College London in partnership with Public Health England, as well as the NIHR HPRU in Immunisation at the London School of Hygiene and Tropical Medicine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thorrington D, van Leeuwen E, Ramsay M, et al. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly. Vaccine. 2019. PMID: 30871927. doi:10.1016/j.vaccine.2019.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。